WORCESTER, Mass., Jan. 19, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today the presentation of the immuno-therapeutics vaccine technology platform and product pipeline of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The podium presentation, entitled “Immunotherapy Using Ii-Key Modified Peptides for Increased, Antigen-Specific T Helper Cell Activation,” was made by Antigen Express President Dr. Eric von Hofe at the Cambridge Healthtech Institutes’ ninth annual PepTalk Conference held in San Diego January 11 – 15, 2010. The symposium highlighted advances in the field of peptide therapeutics and was attended by leaders in academia, industry and regulatory agencies.
